WEST PHARMACEUTICAL SERVICES INC
TD Cowen raised its price target for West Pharmaceutical Services (WST) to $420, maintaining a Buy rating. WST trades at $370.95, 3.1% above its GF Value™ of $359.69, with a GF Score™ of 94/100. The company has strong financial metrics but may be overvalued. Insider selling has been noted.
West Pharmaceutical Services (WST) will release its Q3 2026 financial results on October 29, 2026, before market open. A conference call at 8 a.m. ET will discuss the results and business outlook. A slide presentation and webcast replay will be available on the company's website.
Analysts debate West Pharmaceutical Services' valuation, with some suggesting it may be 17% overvalued due to declining cash flow, while others argue it is 10% undervalued based on execution of higher-margin opportunities. The article also discusses the company's leadership and compensation structure.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning WST (WEST PHARMACEUTICAL SERVICES INC). Coverage has been balanced: 1 bullish, 1 neutral, and 1 bearish.
Recent WST coverage spans financial news, earnings and insider activity.
In the last 30 days, WST insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($1.8M). The most active reporter was Favorite Annette F, Sr. VP & Chief HR Officer, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Street upside bias persists via a higher PT, but the article also flags the stock trading above its cited intrinsic value.
The announcement of the earnings release date provides a clear timing cue for traders to position ahead of the results.
article argues WST is overvalued by 17% because cash flow falls short
Guidance upgrade and large buyback likely support further upside.
The upgrade and price target suggest modest upside potential, but no immediate catalyst.
AlphAI scores every news story that mentions WST with an AI model for sentiment and relevance, and aggregates insider trades from WEST PHARMACEUTICAL SERVICES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
TD Cowen raised its price target for West Pharmaceutical Services (WST) to $420, maintaining a Buy rating. WST trades at $370.95, 3.1% above its GF Value™ of $359.69, with a GF Score™ of 94/100. The company has strong financial metrics but may be overvalued. Insider selling has been noted.
4 min readWest Pharmaceutical Services (WST) will release its Q3 2026 financial results on October 29, 2026, before market open. A conference call at 8 a.m. ET will discuss the results and business outlook. A slide presentation and webcast replay will be available on the company's website.
1 min readAnalysts debate West Pharmaceutical Services' valuation, with some suggesting it may be 17% overvalued due to declining cash flow, while others argue it is 10% undervalued based on execution of higher-margin opportunities. The article also discusses the company's leadership and compensation structure.
2 min readWest Pharmaceutical Services (WST) supplies packaging for injectable drugs, benefiting from demand for biologics and GLP-1 drugs. Despite a 2025 earnings miss, WST has rebounded with Q2 sales growth of 13.8% and raised 2026 guidance. The stock is up 37% YTD, trading at 42x forward earnings. Analysts discuss technical levels and potential breakout.
3 min readWest Pharmaceutical Services (WST) has a 'Strong Buy' rating from 18 analysts, with a mean price target of $401.65, implying a 10% upside from current levels, according to Barchart.com.
1 min readFavorite Annette F (Sr. VP & Chief HR Officer) sold 7,524 shares of WEST PHARMACEUTICAL SERVICES INC (WST) at an average of $355.03 ($345.00–$365.00, $2.67M total) across 3 trades over 2026-09-11 to 2026-09-15 under a Rule 10b5-1 trading plan.
1 min readFavorite Annette F (Sr. VP & Chief HR Officer) sold 8,135 shares of WEST PHARMACEUTICAL SERVICES INC (WST) at $340.81 ($2.77M total) across 3 trades on 2026-09-08.
1 min readAzenta (AZTA) reported Q2 revenue of $161.2M, up 12% YoY, beating estimates. Repligen (RGEN) reported $204.1M, up 11.9% YoY, with mixed guidance. Charles River Labs (CRL) reported $1.0B, down 2.7% YoY, but beat estimates. West Pharmaceutical (WST) reported $872.3M, up 13.8% YoY, beating estimates. Stocks reacted accordingly.
3 min readWall Street analysts covering West Pharmaceutical (WST) have a consensus 'Strong Buy' rating, with 14 'Strong Buy' ratings, one 'Moderate Buy,' and two 'Holds.' The bullish sentiment has slightly decreased from last month. The mean price target of $401.31 suggests a 14.7% upside, while the highest target at $459 implies a 31.2% potential gain.
1 min readWest Pharmaceutical Services (WST) shares rose 38.1% since late March, outpacing its industry and the S&P 500. The company reported 13% organic revenue growth and 29% adjusted EPS growth in Q2, raised its 2026 outlook to 10-11% organic revenue growth, citing HVP demand, Annex 1 upgrades, GLP-1 exposure, and improving manufacturing productivity after a cyber incident.
4 min read
